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Abstract
Introduction: Non-invasive assessment of steatosis and fibrosis is of growing relevance in non-alcoholic fatty liver disease
(NAFLD). 1H-Magnetic resonance spectroscopy (1H-MRS) and the ultrasound-based controlled attenuation parameter (CAP)
correlate with biopsy proven steatosis, but have not been correlated with each other so far. We therefore performed a head-
to-head comparison between both methods.
Methods: Fifty patients with biopsy-proven NAFLD and 15 healthy volunteers were evaluated with 1H-MRS and transient
elastography (TE) including CAP. Steatosis was defined according to the percentage of affected hepatocytes: S1 5-33%, S2
34–66%, S3 $67%.
Results: Steatosis grade in patients with NAFLD was S1 36%, S2 40% and S3 24%. CAP and 1H-MRS significantly correlated
with histopathology and showed comparable accuracy for the detection of hepatic steatosis: areas under the receiver-
operating characteristics curves were 0.93 vs. 0.88 for steatosis $S1 and 0.94 vs. 0.88 for $S2, respectively. Boot-strapping
analysis revealed a CAP cut-off of 300 dB/m for detection of S2-3 steatosis, while retaining the lower cut-off of 215 dB/m for
the definition of healthy individuals. Direct comparison between CAP and 1H-MRS revealed only modest correlation (total
cohort: r = 0.63 [0.44, 0.76]; NAFLD cases: r = 0.56 [0.32, 0.74]). For detection of F2–4 fibrosis TE had sensitivity and specificity
of 100% and 98.1% at a cut-off value of 8.85 kPa.
Conclusion: Our data suggest a comparable diagnostic value of CAP and 1H-MRS for hepatic steatosis quantification.
Combined with the simultaneous TE fibrosis assessment, CAP represents an efficient method for non-invasive
characterization of NAFLD. Limited correlation between CAP and 1H-MRS may be explained by different technical aspects,
anthropometry, and presence of advanced liver fibrosis.
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Introduction
Hepatic steatosis is commonly observed upon histopathological
evaluation of patients with different chronic liver diseases like
alcoholic or non-alcoholic fatty liver disease (NAFLD), chronic
hepatitis B or C or drug induced liver injuries (e.g. by long-term
corticosteroid or amiodarone exposure) [1,2]. NAFLD is the most
prevalent chronic liver disease in the Western world and affects up
to 30% of the population [3]. Its spectrum ranges from simple
steatosis and steatohepatitis to fibrosis and long-term complica-
tions like liver cirrhosis and hepatocellular carcinoma [4,5]. The
reliable quantification of hepatic steatosis is of growing clinical
relevance, because increasing steatosis may favor progression of
fibrosis [3,6] and limit treatment response, e.g. in patients with
viral hepatitis [7,8]. Moreover, detailed quantification of steatosis
is important in estimating the therapeutic success of different
pharmaceutical treatment options in NAFLD [9,10].
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The current gold standard for the assessment of hepatic steatosis
and associated necroinflammatory activity is liver biopsy. Howev-
er, results can be limited by sampling errors, intra- and inter-
observer variability and difficulties in acquiring repetitive and
longitudinal data due to the invasiveness of the procedure [11,12].
Therefore, a number of imaging or laboratory based methods (e.g.
SteatoTest [13], Fatty Liver Index [14]) have been developed in
the last years to quantify hepatic steatosis non-invasively. Imaging
modalities include ultrasound, computed tomography (CT), and
magnetic resonance imaging (MRI) [15]. Recently, an additional
ultrasound based method named Controlled Attenuation Param-
eter (CAP) has been developed to investigate hepatic steatosis [16].
CAP is included in the transient elastography system (TE), which
uses vibration induced elastic shear-waves for assessment of liver
stiffness. For the 3.5 MHz TE M probe, the CAP algorithm
calculates the attenuation of ultrasonic signals used for character-
ization of the shear-wave propagation. In contrast to conventional
B-mode ultrasound, which is impaired by low sensitivity and
difficulties in differentiating different grades of hepatic steatosis,
CAP has shown adequate performance for the detection and semi-
quantification of steatosis in several biopsy-controlled clinical
studies [17–22].
1H-magnetic resunance spectroscopy (1H-MRS) is a safe and
non-invasive alternative for quantification of hepatic fat content
which offers good reproducibility and detailed investigation of
different liver lobes and has been studied in various clinical studies
[23–26]. Although potential limitations are high costs and
availability of the method, it seems especially helpful in clinical
scenarios in which quantitative data of hepatic steatosis are of
relevance [15].
Both the CAP technology and 1H-MRS reliably estimate the
hepatic fat content and correlate with the histopathological
evaluation of hepatic steatosis [27,28]. However, a direct
comparison between both non-invasive methods has not been
performed yet. These data can be important to determine which
non-invasive imaging method may be used in future clinical
studies to investigate the clinical course of patients with NAFLD.
We therefore performed a cross-sectional trial with head-to-head
comparison between CAP and 1H-MRS.
Patients and Methods
Patients and controls
Between March and December 2012 outpatients with biopsy-
proven NAFLD or NASH and absence of concomitant liver
diseases were invited to participate in the study. Healthy
volunteers without any known liver disease, diabetes mellitus, or
metabolic syndrome were enrolled as control group. Weekly
alcohol consumption above 210 g for men and 140 g for woman
was ruled out for all study participants by a thorough clinical
interview prior to inclusion [1]. In healthy controls, signs of
hepatic steatosis in conventional ultrasound (increased echogenic-
ity pattern of liver parenchyma compared to the right renal cortex
using a conventional convex ultrasound probe) were regarded as
exclusion criterion.
All patients underwent clinical examination, abdominal ultra-
sound, liver stiffness measurement with transient elastography
combined with measurement of controlled attenuation parameter
and laboratory assessment on the same day of presentation. In
addition, 1H-MRS was performed within a time period of three
weeks, in the majority of cases on the day of ultrasound
assessment. Fasting for at least three hours was required prior to
the ultrasound and elastography examinations.
Ethics statement
The study was performed in accordance with the ethical
guidelines of the Helsinki Declaration and was approved by the
local ethics committee (University of Leipzig, register no. 283-11-
22082011). All participants provided written informed consent.
Liver histology
Diagnosis of NAFLD or NASH was based on liver biopsy. The
NAFLD activity score (NAS) was assessed by a single expert
pathologist blinded to the clinical data. Steatosis was defined
according to the number of affected hepatocytes: S1 (5–33%,
‘‘mild’’), S2 (33–66%, ‘‘moderate’’), S3 (.66%, ‘‘severe’’). Fibrosis
was classified according the NAS staging [1,29].
A time interval between liver biopsy and study inclusion of up to
48 months was arbitrary accepted for enrolment in the study
(median interval between biopsy and study inclusion 8.5 months,
range 0–40 months).
Elastography, CAP, and ultrasound
All subjects underwent liver stiffness measurement using the M
probe of transient elastography (Echosens, Paris, France; Software
Version 2.01.4_1889). In brief, the device transmits a mechanical
vibration to the tissue and induces elastical shear-wave propaga-
tion which is tracked by pulse-echo ultrasound signals at a
measuring depth of 2.5 to 6.5 cm [30]. The shear-wave velocity is
directly related to the tissue stiffness and expressed in kPa. TE was
performed in supine position in a right intercostal space. Ten valid
measurements were taken with the M probe according to the
manufacturer’s recommendation. A success rate of .60% was
required for a valid measurement. Examinations with an
interquartile range (IQR) .30% of the median liver stiffness
value were classified as unreliable and excluded from further
analysis [31]. The controlled attenuation parameter (CAP)
represents the ultrasonic attenuation coefficient of the ultrasonic
signals used during the TE examination and is expressed in dB/m.
The technical background has been recently described in detail
[16]. The algorithm is included in the TE software and data are
automatically calculated simultaneously with the liver stiffness
measurement. CAP was only appraised in case of a valid and
reliable TE measurement [16,19].
The distance between skin and liver capsule at the site of TE
measurement was measured using a conventional linear ultra-
sound transducer.
Magnetic resonance spectroscopy and volumetry
MR examinations were performed on a 1.5-T scanner (Achieva
XR, Philips Healthcare, Best, Netherlands) with the patient in
supine position. Single-voxel MR spectra were acquired with the
integrated body coil using a point-resolved spectroscopy (PRESS)
technique and local shimming. Voxels (size 20620620 mm3) were
placed in the right liver lobe (segment VII) trying to avoid bile
ducts and larger vessels. Scans were acquired during free breathing
(using breath triggering) with the following sequence parameters:
repetition time, TR=3,500 ms, echo time, TE= 25 ms, 512 data
points, bandwidth, BW=1,000 Hz/pixel, 40 averages, total
acquisition time, TA=140 s, and without water suppression.
MR spectra were analyzed with a commercial tool that uses an
optimized set of basis functions to determine the relative
concentrations of hepatic lipids (LCModel 6.3, Oakville, Canada).
Calculated peak areas of water and fat were corrected for T2
relaxation applying previously published literature values [32] and
were used to calculate the liver fat content (hepatic fat fraction;
given in %) according to the ratio LFC = Sfat/(Sfat + Swater)
CAP and 1H-MRS for Hepatic Steatosis Assessment
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with Sfat as the sum of the areas under the methyl (0.9 ppm),
methylene (1.3 ppm) and allylic (2.1 ppm) peaks and Swater as the
area under the water peak (4.7 ppm).
The liver volume calculation was performed using a custom-
made software tool (Matlab, MathWorks, Natick, MA, USA). The
liver was manually segmented on the images acquired with an in-
phase/opposed-phase sequence described in Tho¨rmer et al. 2013
[33] trying to avoid bile ducts and larger vessels. The volume of
the visceral adipose tissue (VAT) and subcutaneous adipose tissue
(SAT) was determined using software for automated abdominal fat
quantification [34] in a single slice (10 mm thick) at the level of the
lower end of L3 which represents the best association to the
abdominal fat volume [34–36].
Laboratory assessment, NAFLD fibrosis score, and
PNPLA3 genotyping
Blood samples were collected from all study participants after
the ultrasound examinations. Blood count and serum levels of
aminotransferases (ALT and AST), glycohemoglobin (HbA1c),
ferritin, albumin, and lipids (triglycerides, low density lipoprotein
LDL, and high density lipoprotein HDL) were determined after
fasting . 3 h (43/65 cases fasting . 12 h).
The non-alcoholic fatty liver disease fibrosis score was
calculated as follows Score =21.675 + 0.0376 age (years) +
0.0946body mass index (kg/m2) + 1.136diabetes (yes 1, no 0) +
0.996 AST/ALT ratio 2 0.0136 platelet (Gpt/l) 2 0.666
albumin (g/dl) [37].
Genotyping of PNPLA3 variant p.I148M (rs738409, allele C/
G) was performed according to a previously described protocol
with some modifications [38]. Briefly, we extracted genomic DNA
from peripheral blood leukocytes and performed polymerase chain
reaction (PCR) with subsequent melting curve analysis. PNPLA3
genotypes were determined by analytical melting using a pair of
fluorescent resonance energy transfer (FRET) hybridization probes
complementary to the mutated sequence. Primers and probes were
synthesized according to the published nucleotide sequence
(GenBank: NG_008631): Forward primer 59-CTTATGAAG-
GATCAGGAAAATTAAA-39, Reverse primer 59-GGGACA-
GACCCTGAGGT-39, Anchor probe 59-ACCACGCCTCT-
GAAGGAAGGAGGGATAAG-FL-39, Sensor probe 59-LC610-
CCACTGTAGAACGGCATGAAGC-PH-39.
Statistical analysis
Ordinal and nominal data were collected in a MicrosoftH Excel
file. Statistical analyses were conducted by using MedCalc 12.7
(MedCalc Software, Belgium) and the R statistical package
(Version 2.14.0) and the pROC sub-package for receiver operating
characteristics [39]. Clinical and laboratory data were expressed as
median and range or mean 6 standard deviation (SD), as
appropriate. Elastography, CAP and 1H-MRS results are
presented as boxplots and strip charts.
Fisher’s exact test and chi-square test were used to test for
association of variables. Nonparametric tests were chosen to
compare pseudo-median values of two independent samples
(Mann-Whitney U test) or groups (Kruskal-Wallis test) or expected
trends (one-sided Jonckheere-Terpstra test). The t-test was used for
comparison of mean values of independent samples. For trends in
the mean, an ANOVA with polynomial contrasts was performed,
where the p-value for the linear term was used after verifying that
higher order terms did not contribute significantly. Post-hoc
analyses after finding a group effect looked at all combinations of
pairs or contiguous pairs if a trend test was performed and
corrected for multiple testing using Bonferroni-Holm correction. If
such a correction was employed, the corresponding p-value is
denoted a ‘‘corrected p-value’’. Correlations between variables
were examined using Pearson’s correlation coefficients and the
comparison of two sub-groups used the Fisher z-transform [40]. A
p-value , 0.05 was considered significant.
The potential influence of biopsy age was investigated by
including it both as a continuous and categorial variable in linear/
logistic regressions.
Diagnostic performance of the non-invasive methods was
evaluated using receiver operating characteristic curves. The
probabilities of a true-positive (sensitivity, sens.) and a true-
negative (specificity, spec.) were estimated as the proportions in the
cohort (i.e. maximum likelihood) and Wilson confidence intervals
were constructed. The area under the receiver operating
characteristics curve (AUC) was calculated using the trapezoidal
rule, where confidence intervals were found according to [41].
Cut-off calculation
For the ROC curve analysis, cut-off values optimizing the
Youden index were calculated for comparison with previous
results, some of which implicitly stressed high sensitivity and others
high specificity. In addition, we applied published cut-off-values
for TE and CAP to our study cohort: For TE, a cut-off of 7.9 kPa
has been described for sensitive identification of patients at risk of
advanced NAFLD associated fibrosis in a large biopsy controlled
cohort [42]. More recently, CAP had a sensitivity . 90% for the
detection of hepatic steatosis $ S1 and $ S2 in patients with
chronic liver disease at a cut-off value of 215 and 252 dB/m,
respectively [19].
For the CAP procedure an additional cut-off value considering
the specific clinical diagnostic requirements was determined by
introducing a score to be optimized and estimating the associated
confidence interval with bootstrapping procedures.
Results
Clinical characteristics of the study cohort
We recruited 53 patients with NAFLD and 17 healthy
volunteers. However, three patients had histological and clinical
features of concomitant autoimmune or cholestatic liver disease.
Two control cases showed signs of liver disease (one with steatotic
liver ultrasound pattern, one with elevated aminotransferases) and
were excluded. Therefore, 50 patients with NAFLD and 15
healthy controls were included in the final analysis.
Patients with NAFLD were classified by a single expert
pathologist according to the histological degree of steatosis: 18,
20, and 12 cases had mild (S1), moderate (S2), and severe (S3)
steatosis, respectively [1,29]. Fibrosis staging revealed F0, F1, F2,
F3, and F4 fibrosis in 10, 32, 2, 3, and 3 cases. The associations
between CAP, 1H-MRS and histology were essentially unaffected
by the age of the biopsy (all p-values . 0.3).
Clinical characteristics of the study cohort are presented in
table 1. Gender distribution did not differ significantly between the
three NAFLD subgroups and only slight differences in age were
observed. Time span since liver biopsy did not differ significantly.
NAFLD cases with mild steatosis (S1) had a lower prevalence of
hepatocellular inflammation (NASH) (n = 4/18 vs. 22/32,
p = 0.003), arterial hypertension (n= 4/18 vs. 20/32, p = 0.008),
and a trend towards a lower prevalence of diabetes mellitus type 2
(n= 2/18 vs. 12/32, p = 0.056) compared to patients with more
advanced steatosis (S2 and S3). Moreover, S2 and S3 patients had
a higher frequency of the non-CC PNPLA3 genotype (n = 22/32
vs. 4/18, p= 0.003) and a trend towards a higher risk profile
according to the NAFLD score (intermediate/high risk n= 16/32
vs. 4/18, p = 0.074) (table 1).
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Transient elastography and performance of CAP
Valid and reliable TE and CAP results could be obtained in all
control cases (100%) and 46/50 patients with NAFLD (92%).
Patients with fibrosis stage F2–4 (n = 8) had higher median TE
values (18.0 kPa) compared to NAFLD cases with stage F0–1 and
controls (4.8 kPa, n= 53), 95% CI for increase in median [9.0,
22.4] kPa, p,0.0001. The ROC curve analysis for differentiation
between F0–1 and F2–4 fibrosis revealed a high accuracy
(sensitivity 100% [67.6, 100]%, specificity 98.1% [90.1, 99.9]%,
AUC 0.991 [0.971, 1]) at a cut-off value of 8.85 kPa.
Median CAP values increased significantly with the degree of
hepatic steatosis (p , 0.0001) and differed by an estimated 52 dB/
m ([19, 80] dB/m, corrected p= 0.002) between the controls and
S1 and by 67 dB/m ([40, 80] dB/m, corrected p= 0.0001)
between S1 and S2 (table 2, figure 1A). ROC curve analysis
revealed a high accuracy for differentiation between absence vs.
any degree of steatosis (S0 vs. S1–3, AUC 0.930 [0.865, 0.996])
and mild vs. moderate/severe (S0–1 vs. S2–3, AUC 0.934 [0.883,
0.994]) hepatic steatosis, whereas the area under the curve for
differentiation between S0–2 and S3 steatosis was 0.816 [0.701,
0.932] (table 3).
MR imaging and performance of MR spectroscopy
All healthy subjects and 48 patients with NAFLD (96%)
underwent MRI examinations. One patient was excluded from
MRI due to a contraindication (pacemaker), one patient refused
examination because of claustrophobia. In addition, 1H-MRS data
from one healthy volunteer were lost due to a technical error
during data acquisition.
Liver volume and visceral fat volume showed a stepwise increase
compared to the degree of hepatic steatosis. A similar trend was
Table 1. Baseline characteristics of the study cohort.
Healthy Controls Patients with NAFLD
Degree of steatosis NAS (S0) S1 S2 S3
Anthropometry
sex male/female 6/9 11/7 9/11 5/7
age* years 38.5 6 11.8 50.4 6 12.9 60.0 6 7.5 54.7 6 9.1
BMI* kg/m2 22.9 6 2.4 25.9 6 4.1 29.0 6 4.0 33.0 6 4.9
waist-to-hip* ratio 0.86 6 0.13 0.90 6 0.09 0.96 6 0.08 0.96 6 0.06
Comorbidities
diabetes mell. type 2 n 0 2 (11%) 6 (30%) 6 (50%)
arterial hypertension n 0 4 (22%) 12 (60%) 8 (67%)
Histology
time since biopsy* months - 14.8 6 14.4 13.3 6 12.9 17.6 6 14.6
fibrosis F0 (15) 8 1 1
F1 - 9 14 9
F2 - 0 1 1
F3 - 0 2 1
F4 - 1 2 0
inflammation absent/present (15/0) 14/4 6/14 4/8
PNPLA3 genotyping
rs738409 CC/CG/GG n 8/6/1 14/4/0 7/10/3 3/8/1
NAFLD Score
low risk n 14 14 11 5
indeterminate risk n 1 3 7 7
high risk n 0 1 2 0
Laboratory values
ALT/ULN* ratio 0.43 6 0.09 1.20 6 1.13 1.32 6 1.06 1.04 6 0.31
AST/ULN* ratio 0.53 6 0.10 0.89 6 0.44 1.07 6 0.63 0.98 6 0.40
GGT/ULN* ratio 0.41 6 0.24 2.51 6 3.43 2.05 6 1.82 1.98 6 2.13
HbA1c* (%) 4.98 6 0.21 5.14 6 0.50 5.56 6 0.71 6.04 6 0.96
ferritin/ULN*,** ratio 0.50 6 0.56 0.82 6 0.70 1.08 6 0.77 0.88 6 0.85
triglycerides* (mmol/l) 0.97 6 0.49 1.17 6 0.51 1.77 6 0.89 2.18 6 1.19
LDL cholesterol* (mmol/l) 2.74 6 0.80 3.48 6 0.82 3.49 6 1.08 3.59 6 1.19
HDL cholesterol* (mmol/l) 1.90 6 0.43 1.77 6 0.62 1.39 6 0.44 1.41 6 0.39
* values presented as mean and standard deviation.
** values missing in three individuals (2x S1, 2x S3).
Abbreviations: BMI – body mass index, ULN – upper limit of normal.
doi:10.1371/journal.pone.0091987.t001
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observed for the subcutaneous fat volume (post-hoc analyses could
verify only that it was significant for S0 vs. S3 however) (table 2).
The median hepatic fat fraction measured by 1H-MRS also
increased significantly with the degree of hepatic steatosis (p,
0.001) with an estimated change of 3 percentage points ([1,6],
corrected p= 0.01) between the control group and S1, of 9
percentage points ([2,14], corrected p= 0.01) between S1 and S2
and an estimated 6 percentage points ([21, 13], p = 0.1) between
S2 and S3 (table 2, figure 2). All degrees (S1–3), moderate/severe
(S2–3), and severe (S3) hepatic steatosis were detected with good
accuracy (AUC . 0.85, lower end of 95% CI . 0.75) (table 3,
figure 1B).
Comparison of CAP and MR spectroscopy
Correlation of CAP and 1H-MRS was analyzed using Pearson’s
correlation coefficient. Both methods correlated modestly in the
total study cohort (n = 58 with available valid CAP and 1H-MRS
results, r = 0.63 [0.44, 0.76], p,0.001), while analysis of NAFLD
cases only resulted in an even weaker correlation (n = 44; r = 0.56,
[0.32, 0.74], p,0.001). We therefore further analyzed the
influence of liver fibrosis on correlation between CAP and 1H-
MRS: the correlation in patients with biopsy proven liver fibrosis
F2–4 (n= 8, r =20.2, [20.8, 0.6]) differed significantly from the
correlation for those with no or mild fibrosis (F0–1) (r = 0.7, [0.5,
0.8]), in whom the comparison of these correlations resulted in p,
0.0001 (figure 2). The individuals with F2–4 fibrosis showed higher
ferritin levels compared to cases with F0–1 fibrosis (median
113%ULN vs. 59%ULN, difference in pseudo-median 70
percentage points [11, 207], p = 0.02).
Cut-off values for clinical use
Applying a TE cut-off value of 7.9 kPa [42] to our cohort
resulted in 100% [68, 100]% sensitivity for the detection of F2–4
fibrosis with a specificity of 94% [85, 98]%. Similarly, a CAP cut-
off of 252 dB/m resulted in a 100% [89%, 100%] sensitivity for
detecting and S2–3 steatosis, but a specificity of only 71% [53%,
84%] (figure 3A). At the 252 dB/m threshold, steatosis quantifi-
cation was accurate for controls and patients with steatosis S2 and
S3, while 8/16 (50%) of S1 patients with valid CAP results were
misclassified. These eight patients had a trend toward a higher
BMI (27.064.1 vs. 23.662.3 kg/m2, p = 0.06), NAFLD score (2
1.461.6 vs. 23.061.2, p = 0.04) and skin-to-liver-capsule distanc-
es (20.863.3 vs. 17.562.1, p= 0.03) compared to correctly
classified S1 patients. Only one of the misclassified patients had
a skin-to-liver-capsule distance above 25 mm (27.2 mm).
In clinical practice diagnostic tests with high specificity are
required [43]. This requirement cannot be met with a single cut-
off and we thus chose to employ a second, higher one, which will
permit us to improve specificity at the price of introducing the
category of ‘‘unclassified’’ patients requiring further testing.
We did so by determining the CAP value for the detection of
steatosis $ S2 that maximizes the score
score = (true positives + 0.5 true negatives 23 false positives –
false negatives 20.25 unclassified)/(n_patients + 0.5 n_control)
which has the value 1 for a perfect test. While the choice of four
coefficients may seem to permit a large amount of arbitrariness, we
point out that other methods, such as optimizing a ROC curve or
the sensitivity, make similar choices implicitly. They lack however
the freedom to provide a weight to each item as appropriate to the
diagnosis under scrutiny.
This calculation revealed a cut-off of 301 dB/m. Bootstrapping
(5000 times repetition) with a random selection of half the data
points results in a median cut-off of 294 dB/m with 95% of the
values in the interval [257, 345] dB/m. We therefore used a cut-off
of 300 dB/m for the detection of S2–3 steatosis to obtain high
specificity, while retaining the lower cut of 215 dB/m for the
definition of healthy individuals (figure 3B). Applying these cut-offs
to the 61 patients/controls with valid CAP measurements results
in 20 true positive and one false negative diagnosis, 9 true negative
and no false negative cases and 31 who are unclassified and
require further testing. The implications regarding positive and
negative predictive values and the proportion of unclassified cases
can be found in figure 4. There, one can see that predictive values
are above 80% for prevalences roughly between 0.25 and 0.7, but
with 40 to 60% of the patients remaining uncharacterized.
Discussion
Non-invasive hepatic fat quantification has a growing impor-
tance for the diagnosis and monitoring of hepatic steatosis [15,16].
To our knowledge, this is the first study that provides a head-to-
head comparison of the ultrasound based CAP technology and
MR spectroscopy for hepatic steatosis quantification. CAP is
Table 2. Elastography, Controlled attenuation parameter (CAP) and magnetic resonance imaging.
Healthy Controls NAFLD Patients – degree of steatosis p-value
(S0) S1 S2 S3
Transient Elastography valid/all 15/15 16/18 19/20 11/12 0.6
skin-to-liver-capsule distance* mm 16.3 6 2.7 19.7 6 3.7 23.5 6 6.4 26.2 6 5.3 p , 0.0001
liver stiffness** kPa 4.4 [2.3–5.9] 4.8 [1.9–59.3] 5.3 [2.7–70.6] 5.4 [3.5–21.8] p = 0.003
CAP* dB/m 201 6 44 253 6 43 321 6 42 335 6 43 p , 0.0001
Magnetic resonance imaging available (n) 15 18 19 11 -
liver volume* ml 1346 6 223 1435 6 353 1746 6 394 2067 6 390 p , 0.0001
subcutaneous fat volume (L3)* ml 240 6 116 283 6 81 318 6 99 384 6 109 p = 0.002
visceral fat volume (L3)* ml 75 6 106 113 6 59 194 6 103 247 6 137 p , 0.00001
1H-MRS (segment VII)** rel. lipid signal 0.8 [0–8.6]# 5.2 [0.9–33.7] 15.4 [1.6–32.3] 22 [8.2–34.9] p , 0.00001
* values presented as mean and standard deviation
** values presented as median and range
#available in 14 cases of the control cohort
Abbreviations: MRS – magnetic resonance spectroscopy
doi:10.1371/journal.pone.0091987.t002
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calculated from the TE ultrasound signal attenuation and can
therefore only be acquired given a successful TE measurement
[27]. Thus, limitations of TE – mainly obesity – likewise impair
CAP feasibility [27,31,44]. In addition, influencing factors on CAP
accuracy and quality standards (e.g. exclusion of results with high
IQR values) are not yet defined [18,19]. In our study cohort,
although CAP results were only considered when TE fulfilled the
commonly accepted quality criteria [19], a high success rate was
Figure 1. CAP (A) and 1H-MRS (B) correlate with hepatic steatosis. CAP and 1H-MRS values correlate with the amount of hepatic fat and show
a stepwise increase compared to the NAS staging (61 and 62 valid measurements available, respectively).
doi:10.1371/journal.pone.0091987.g001
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observed for both healthy individuals (100%) and patients with
NAFLD (92%).
1H-MRS techniques expluit the difference in resonance
frequencies between water and fat signals for estimation of hepatic
fat concentration and usually have a high feasibility (.90% in our
cohort) [28]. Their application is limited by implanted medical
devices and claustrophobia, and can also be impaired by severe
obesity [45].
CAP and 1H-MRS each correlated fairly well with biopsy
proven steatosis and significantly differentiated between S0, S1
and S2 patients (figure 1). However, a significant difference could
not be detected in subjects with advanced disease (S2–S3), which is
in line with the CAP data of Myers et al. [18] and de Ledinghen et
Table 3. Diagnostic performance for detection of hepatic steatosis at optimal cut-off (optimizing the Youden Index).
CAP 1H-MRS
S0 (controls) vs. S1–3 cases (n)# 15/46 14/48
Sensitivity 93% [80, 100]% 79% [57, 100]%
Specificity 87% [76, 96]% 88% [77, 96]%
AUC* 0.93 [0.86, 1.00] 0.88 [0.78, 0.99]
cut-off 233.5 dB/m 3.12% fat fraction
S0–1 vs. S2–3 cases (n)# 31/30 32/30
Sensitivity 97% [90, 100]% 91% [81, 100]%
Specificity 81% [64, 94]% 77% [60, 90]%
AUC* 0.94 [0.88, 0.99] 0.88 [0.79, 0.97]
cut-off 268.5 dB/m 8.77% fat fraction
S0–2 vs. S3 cases (n)# 50/11 51/11
Sensitivity 82% [55, 100]% 91% [73, 100]
Specificity 76% [64, 88]% 75% [63, 86]
AUC* 0.82 [0.70, 0.93] 0.85 [0.75, 0.95]
cut-off 301.2 dB/m 13.69% fat fraction
#Only patients with valid measurements were considered for this analysis.
* Comparison of CAP and 1H-MRS ROC curves did not reveal significant differences of AUC.
doi:10.1371/journal.pone.0091987.t003
Figure 2. Correlation of CAP and 1H-MRS. CAP and 1H-MRS achieved only a modest correlation, especially in patients with concomitant fibrosis
(labeled with squares). A total of 61 valid measurements were available.
doi:10.1371/journal.pone.0091987.g002
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al. [19] and may limit adequate monitoring of steatosis changes in
these patients.
In the head-to-head comparison between both methods, CAP
and 1H-MRS achieved only a modest correlation, especially in
patients with concomitant fibrosis (figure 2). In these individuals
increased serum ferritin levels suggest NASH associated hepatic
iron deposition [46] which can interfere with MR-based steatosis
assessment and thus may have contributed to imprecise liver fat
quantification [47,48]. Correlation may be further impaired by
anthropometrical characteristics like high BMI or large skin to
liver capsule distance, which can affect accuracy of transient
elastography and hence CAP [22,49,50] and cannot be assessed
without the additional use of ultrasound.
Anthropometrically related limitations of the TE and CAP
technology may be overcome by further development of the TE
XL probe. At present, CAP is only available for the M probe of the
transient elastography system which reduces feasibility and
reliability in patients with BMI values . 28 kg/m2 and high
skin-to-liver capsule distances [51]. Implementation of CAP in the
TE XL probe, which is designed for liver stiffness assessment in
obese patients, may overcome this limitation in the future [27,51].
Considering non-invasive methods as an alternative to liver
biopsy, cut-off values for steatosis grading are required. Our 1H-
MRS cut-off value for the detection of any steatosis grade (3.12%
fat fraction) corresponds to data from Szczepaniak et al. who
determined a hepatic fat fraction signal of 5.56% as upper 95th
Figure 3. CAP and TE cut-off values for clinical use. Application of published cut-off values for TE (7.9 kPa) and CAP (252 dB/m2) results in high
sensitivity for detection of distinct fibrosis and steatosis (A) [19,43]. CAP values between 215 dB/m [19] and 300 dB/m require further diagnostic
procedures for differentiation of the degree of steatosis (‘‘grey area’’) (B).
doi:10.1371/journal.pone.0091987.g003
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percentile in healthy individuals [23]. However, further biopsy
controlled studies applying 1H-MRS did not provide cut-off values
thus rendering a comparison difficult [17,52,53].
Our CAP cut-off values for different grades of hepatic steatosis
are in line with data from previous biopsy controlled studies
evaluating CAP in various chronic liver diseases [17–21]. To date,
CAP and 1H-MRS results show a distinct overlap between
NAFLD subgroups (figure 1) which affects correct classification in
a considerable proportion of patients: depending on the applied
cut-off value and the estimated prevalence of steatosis in the
population of interest, CAP correctly classifies 50% of individuals
with absent/mild (S0–1) or moderate/severe (S2–3) steatosis
(figure 3b, figure 4). The introduction of two cut-offs is important
for dealing with this issue and improving the predictive value of
the technique. We point out that one cannot expect, or even strive
for very high predictive values so long as the gold standard itself
contains a considerable amount of error. As described above, this
is the case with biopsies, meaning that the ‘‘correct’’ diagnosis itself
may be erroneous in a considerable fraction of cases [11,12].
However, care for patients with NAFLD in clinical practice
requires not only grading of hepatic steatosis, but precise cut-off
values for identification of ‘‘healthy’’ and ‘‘sick’’ individuals.
Therefore, a clear diagnostic and therapeutic concept is necessary
when non-invasive methods of steatosis grading are implemented
in clinical routine or as diagnostic tools in clinical studies with
special regard to patients assigned to the ‘‘grey area’’: Careful
patient selection, consideration of interfering factors (e.g. body
mass index, skin to liver capsule distance, fibrosis) and combina-
tion of different methods may improve the diagnostic accuracy of
non-invasive liver assessment and underline its potential as a
guidance to liver biopsy [54]. Longitudinal studies are required to
define the value of CAP as a monitoring tool for hepatic steatosis
in interventional studies.
In addition to the steatosis evaluation with the CAP technology,
transient elastography could simultaneously diagnose hepatic
fibrosis. Applying the cut-off value of 7.9 kPa, which has been
proposed for patients with NAFLD with F3-4 fibrosis by Wong et
al. [42], fibrosis could be detected in all individuals at risk for
disease progression (cases with F2–F4 fibrosis) in our cohort
(figure 3A). Differences in the classification of F2 patients in our
study compared to Wong et al. may be related to the baseline
characteristics of the study cohorts, as Wong et al. included 48%
individuals with Chinese ethnicity [42] and the low case numbers.
Thus, transient elastography with the M probe and simultaneous
CAP measurement are promising tools to non-invasively charac-
terize major histopathological aspects of patients with NAFLD. In
the future, these methods have to prove recent data for the
NAFLD fibrosis score which could show that non-invasive
characterization of NAFLD better predicts long-term outcome
than histology [55].
Our study has some limitations:
i) We used liver histology as a reference standard for steatosis
grading and fibrosis staging. Histology classifies steatosis
according to the number of affected hepatocytes without
assessing the hepatic triglyceride concentration [29]. This
limits its comparability with hepatic fat fraction measurement
by 1H-MRS and ultrasound signal attenuation calculation by
CAP. In this regard, further biopsy controlled longitudinal
studies are required to determine whether the proportion of
affected hepatocytes, the type of steatosis (micro- or
macrovesicular), or the hepatic lipid concentration are the
best marker for disease severity and risk of progression.
ii) We cannot exclude alteration of histological NAFLD features
during the time interval from biopsy to study inclusion.
Although unlikely for simple steatosis [56], significant disease
Figure 4. Positive and negative predictive values as well as proportion of uncharacterized cases as they depend upon prevalence.
S0–1 patients and controls were classified as healthy and S2–3 as sick. The diagnostic procedure made use of CAP where those with values below
215 dB/m were diagnosed as healthy, those with values above 300 dB/m (or 252 dB/m, dashed lines) were diagnosed as sick and those in between
were not diagnosed. A total of 61 valid measurements were available.
doi:10.1371/journal.pone.0091987.g004
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progression may have contributed to the finding of narrow
differences of CAP and 1H-MRS results in patients with S2
and S3 steatosis. Our analyses could not detect any such
effect however. In addition, liver biopsies were not performed
as part of our study examinations for ethical reasons as this
invasive procedure would not have influenced the clinical
management in our NAFLD patients.
iii) Our results were acquired in a NAFLD population with a
limited prevalence of advanced liver damage (16% of cases
with $F2 fibrosis). Therefore, further studies are required to
investigate the correlation of CAP and 1H-MRS in cohorts
with advanced NAFLD stages.
In conclusion, our pilot data suggest a comparable diagnostic
accuracy of CAP and 1H-MRS for non-invasive characterization
of hepatic steatosis. Together with the simultaneous fibrosis
assessment by transient elastography, it represents a fast and easy
to use method to characterize patients with NAFLD non-
invasively. Considering the increasing NAFLD prevalence, its
growing medical impact, and the need for easy, repetitive, and
reliable diagnostic tools, it is encouraging that CAP can already
correctly classify 50% of individuals with values ,215 dB/m
excluding hepatic steatosis and results .300 dB/m identifying .
33% steatosis.
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